BB Biotech AG (BION.SW)
CHF 36.75
(0.68%)
CHF 36.75
(0.68%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -201.25 Million CHF | 41.99% |
| 2022 | -357.28 Million CHF | 12.04% |
| 2021 | -402.79 Million CHF | -158.55% |
| 2020 | 691.24 Million CHF | 2.03% |
| 2019 | 677.49 Million CHF | 244.09% |
| 2018 | -429.63 Million CHF | -168.33% |
| 2017 | - CHF | 185.92% |
| 2016 | -801.14 Million CHF | -222.64% |
| 2015 | - CHF | -55.6% |
| 2014 | - CHF | 57.64% |
| 2013 | - CHF | 151.6% |
| 2012 | -1.17 Million CHF | 670.04% |
| 2011 | -65.05 Million CHF | 55.53% |
| 2010 | - CHF | -490.83% |
| 2009 | - CHF | -17.58% |
| 2008 | -8.02 Million CHF | 117.1% |
| 2007 | -265.52 Million CHF | -189.32% |
| 2006 | - CHF | -6.46% |
| 2005 | - CHF | 56.68% |
| 2004 | -215.77 Million CHF | 13.0% |
| 2003 | - CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | - CHF | 100.0% |
| 2024 Q1 | -1.45 Million CHF | -133.16% |
| 2024 Q2 | -79.36 Million CHF | -1.19% |
| 2023 FY | - CHF | 41.99% |
| 2023 Q4 | 109.15 Million CHF | 325.63% |
| 2023 Q3 | -48.37 Million CHF | -259.29% |
| 2023 Q2 | -13.46 Million CHF | 94.67% |
| 2023 Q1 | -252.73 Million CHF | -618.78% |
| 2022 FY | - CHF | 12.04% |
| 2022 Q4 | -35.16 Million CHF | -116.72% |
| 2022 Q2 | -232.7 Million CHF | 22.33% |
| 2022 Q3 | 210.29 Million CHF | 190.37% |
| 2022 Q1 | -299.59 Million CHF | 12.98% |
| 2021 FY | - CHF | -158.55% |
| 2021 Q1 | 220.96 Million CHF | 13672.91% |
| 2021 Q2 | 128.56 Million CHF | -41.82% |
| 2021 Q3 | -193.04 Million CHF | -250.15% |
| 2021 Q4 | -344.27 Million CHF | -78.34% |
| 2020 Q3 | -383.42 Million CHF | -124387.01% |
| 2020 FY | - CHF | 2.03% |
| 2020 Q4 | -1.62 Million CHF | 99.58% |
| 2020 Q2 | -308 Thousand CHF | -64.71% |
| 2020 Q1 | -187 Thousand CHF | 84.14% |
| 2019 Q4 | -1.17 Million CHF | 99.68% |
| 2019 Q2 | 46.02 Million CHF | -85.77% |
| 2019 Q1 | 323.34 Million CHF | 175.58% |
| 2019 FY | - CHF | 244.09% |
| 2019 Q3 | -370.6 Million CHF | -905.2% |
| 2018 Q4 | -427.83 Million CHF | -63188.46% |
| 2018 Q2 | -88.42 Million CHF | -333.8% |
| 2018 FY | - CHF | -168.33% |
| 2018 Q1 | 37.82 Million CHF | 23590.68% |
| 2018 Q3 | -676 Thousand CHF | 99.24% |
| 2017 Q4 | -161 Thousand CHF | -120.91% |
| 2017 Q3 | 770 Thousand CHF | -99.26% |
| 2017 Q2 | 103.66 Million CHF | -72.37% |
| 2017 FY | - CHF | 185.92% |
| 2017 Q1 | 375.21 Million CHF | 1666.9% |
| 2016 Q4 | -23.94 Million CHF | -106.1% |
| 2016 Q1 | -1.2 Billion CHF | -335.6% |
| 2016 Q3 | 392.41 Million CHF | 993.5% |
| 2016 FY | - CHF | -222.64% |
| 2016 Q2 | 35.88 Million CHF | 102.98% |
| 2015 Q3 | -575.39 Million CHF | -270.5% |
| 2015 FY | - CHF | -55.6% |
| 2015 Q4 | 511.57 Million CHF | 188.91% |
| 2015 Q2 | 337.48 Million CHF | -11.05% |
| 2015 Q1 | 379.41 Million CHF | -47.77% |
| 2014 Q4 | 726.4 Million CHF | 50.4% |
| 2014 Q3 | 482.98 Million CHF | 146.89% |
| 2014 Q2 | 195.62 Million CHF | 197.52% |
| 2014 FY | - CHF | 57.64% |
| 2014 Q1 | 65.75 Million CHF | -34.59% |
| 2013 Q2 | 134.2 Million CHF | -62.59% |
| 2013 Q3 | 339.44 Million CHF | 152.92% |
| 2013 Q4 | 100.52 Million CHF | -70.39% |
| 2013 FY | - CHF | 151.6% |
| 2013 Q1 | 358.79 Million CHF | 366.93% |
| 2012 Q2 | 160.12 Million CHF | -17.25% |
| 2012 Q3 | 148.64 Million CHF | -7.17% |
| 2012 Q4 | -134.41 Million CHF | -190.43% |
| 2012 Q1 | 193.49 Million CHF | 78.17% |
| 2012 FY | - CHF | 670.04% |
| 2011 Q3 | -128.98 Million CHF | -50.22% |
| 2011 Q1 | 38.1 Million CHF | -43.05% |
| 2011 FY | - CHF | 55.53% |
| 2011 Q4 | 108.6 Million CHF | 184.2% |
| 2011 Q2 | -85.86 Million CHF | -325.34% |
| 2010 Q3 | 33.56 Million CHF | 111.64% |
| 2010 Q4 | 66.9 Million CHF | 99.35% |
| 2010 Q1 | 41.45 Million CHF | 156.46% |
| 2010 FY | - CHF | -490.83% |
| 2010 Q2 | -288.22 Million CHF | -795.28% |
| 2009 Q2 | 93.29 Million CHF | 201.46% |
| 2009 Q3 | 109.51 Million CHF | 17.39% |
| 2009 Q4 | -73.41 Million CHF | -167.04% |
| 2009 FY | - CHF | -17.58% |
| 2009 Q1 | -91.95 Million CHF | 0.0% |
| 2008 FY | - CHF | 117.1% |
| 2007 FY | - CHF | -189.32% |
| 2006 FY | - CHF | -6.46% |
| 2005 FY | - CHF | 56.68% |
| 2004 FY | - CHF | 13.0% |
| 2003 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.22 Million CHF | -1867.569% |
| Basilea Pharmaceutica AG | 29.49 Million CHF | 782.339% |
| Evolva Holding SA | -98.35 Million CHF | -104.617% |
| Idorsia Ltd | -254.55 Million CHF | 20.937% |
| Kuros Biosciences AG | -10.4 Million CHF | -1833.481% |
| Molecular Partners AG | -59.51 Million CHF | -238.16% |
| Relief Therapeutics Holding AG | -108.2 Million CHF | -86.0% |
| Santhera Pharmaceuticals Holding AG | 79.17 Million CHF | 354.195% |